Placebo Outperforms TG-C: Data Errors and Stock Volatility Cloud Kolon TissueGene’s Phase 3 Trial
Kolon TissueGene’s knee osteoarthritis cell and gene therapy, TG-C, has failed to achieve statistical significance on its primary endpoints in its...
Biowatch
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.6% in Phase 3 clinical trials, though it did...
Celltrion Files for EU Approval of Cosentyx Biosimilar CT-P55, Targeting $6.7 Billion Autoimmune Market
Celltrion announced on the 24th that it has submitted a marketing authorization application to the European Medicines...
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition
A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...
Daewoong Pharmaceutical Cuts Off Hospital Sales After Domestic Nabota Vials Surface in the U.S.
Daewoong Pharmaceutical announced on July 23 that it has severed supply transactions with a domestic medical...
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data
HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...
Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms
Samsung Biologics reported second-quarter revenue in the 1.3 trillion won range this year, a 30% increase from the same...
117 Workplace Accidents Recognized at 25 Major Korean Pharma and Biotech Firms Over Five Years
A review of 25 major South Korean pharmaceutical and biotechnology companies revealed 117 recognized industrial...
Biogen Korea Taps Pharma Veteran Kim Chul-woong as New Country Lead
Biogen Korea has appointed Kim Chul-woong as its new general manager, tapping an executive with extensive expertise in...
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal
Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...